Cell Line Description:
The HCC2218 cell line was initiated on April 10, 1996, and took 6 months to establish. HCC2218 was derived from a female whose family members included several members with cancer, four lung cancer patients (two of them, non-smokers), two breast cancer patients (one of them also had lung cancer) and one colon cancer patient. HCC2218 is a poorly differentiated cell line derived from the primary tumor of an invasive ductal carcinoma with metastases in 42/43 lymph nodes. The cells are highly positive for expression of Her2/neu, and are also positive for expression of p53. HCC2218 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 [EGP2] and for cytokeratin 19. The cells are negative for expression of estrogen receptor (ER -), but positive for expression of progesterone receptor (PR +). DNA was isolated from an EBV-transformed lymphoblastoid cell line, HCC2218 BL, from the same patient is available as ATCC CRL-2363D.
Quality Control Specifications
DNA Quality Control Information:
· > 100 kb in size by agarose gel electrophoresis
· No RNA detected in the agarose gel
· A260/A280 ratio ³ 1.8
· Tested and verified for PCR amplification and restriction digestion.